JPMorgan Chase & Co. Has $83.61 Million Stake in Twist Bioscience Co. (NASDAQ:TWST)

JPMorgan Chase & Co. lessened its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 27.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,799,212 shares of the company's stock after selling 676,061 shares during the period. JPMorgan Chase & Co. owned approximately 3.02% of Twist Bioscience worth $83,609,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TWST. EntryPoint Capital LLC bought a new position in shares of Twist Bioscience during the fourth quarter valued at $420,000. Vanguard Group Inc. lifted its holdings in Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the last quarter. Fox Run Management L.L.C. boosted its position in Twist Bioscience by 57.9% in the fourth quarter. Fox Run Management L.L.C. now owns 16,739 shares of the company's stock valued at $778,000 after buying an additional 6,138 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Twist Bioscience during the fourth quarter worth about $562,000. Finally, Hillsdale Investment Management Inc. increased its holdings in shares of Twist Bioscience by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock worth $3,625,000 after buying an additional 300 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a report on Friday, March 28th. Barclays set a $58.00 price target on Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average price target of $54.10.

Remove Ads

Twist Bioscience Price Performance

TWST traded down $1.81 during trading on Tuesday, hitting $35.18. 1,308,995 shares of the stock traded hands, compared to its average volume of 965,015. The business has a 50 day moving average price of $42.87 and a 200 day moving average price of $44.85. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -10.41 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm's quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the company posted ($0.75) EPS. Equities research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the business's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the sale, the director now directly owns 18,173 shares of the company's stock, valued at $965,531.49. The trade was a 13.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dennis Cho sold 806 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares of the company's stock, valued at $5,538,106.35. The trade was a 0.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,682 shares of company stock worth $1,332,011. Insiders own 3.01% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.